John C. Pesko

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Vinod Pullarkat, Norman J. Lacayo, Elias Jabbour et al. · Cancer Discovery · 2021 · 270 citations · Full text

Targeting <scp>BCL</scp>‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

Jonathan L. Kaufman, Cristina Gasparetto, Fredrik Schjesvold et al. · American Journal of Hematology · 2020 · 105 citations · Full text

Hypoxia promotes tau hyperphosphorylation with associated neuropathology in vascular dysfunction

Limor Raz, Kiran Bhaskar, John Weaver et al. · Neurobiology of Disease · 2018 · 81 citations · Full text

Physiology, Hypoxia (Medicine), Degenerative Pathology +8

Safety and efficacy of navitoclax, a BCL-2 and BCL-X _L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

Sven de Vos, John P. Leonard, Jonathan W. Friedberg et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 81 citations · Full text

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

Matthew S. Davids, Andrew W. Roberts, Vaishalee P. Kenkre et al. · Clinical Cancer Research · 2021 · 67 citations · Full text